Bluejay Diagnostics, Inc. (BJDX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Indranil Dey | Principal Financial, Accounting & Executive Officer, President, CEO and Director | 292.15k | -- | 1964 |
| Dr. Jason Cook | Chief Technology Officer | 240.29k | -- | 1983 |
| Mr. Les DeLuca | Vice President of Operations | -- | -- | -- |
| Eryn Graham | Marketing Manager | -- | -- | -- |
| Mr. Kevin Vance | Chief Commercial Officer | -- | -- | 1958 |
| Mark W. Feinberg | Chief Medical Advisor | -- | -- | -- |
| Dr. Mark W. Feinberg M.D. | Chief Medical Advisor | -- | -- | -- |
| Ryan McSeveney | Corporate Controller | -- | -- | -- |
Bluejay Diagnostics, Inc.
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 10
Description
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Corporate Governance
Recent Events
- Apr 15, 2024DEF 14A: Proxy StatementsSee Full Filing
- Apr 05, 2024PRE 14A: Proxy StatementsSee Full Filing
- Apr 02, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 28, 202410-K: Periodic Financial ReportsSee Full Filing
- Mar 04, 20248-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
Upcoming Events Information Not Available